Genitourinary Cancer Incidence and Mortality Varies by Region, Race, and Sex
Incidence and mortality rates for major genitourinary cancers differ according to sex, race/ethnicity, and geographic region.
Incidence and mortality rates for major genitourinary cancers differ according to sex, race/ethnicity, and geographic region.
Oncology drug approvals in the United States are increasingly supported by single-arm clinical trials, a study suggests.
Black cancer patients are less likely than their White counterparts to receive shorter radiotherapy regimens, a study suggests.
Some patients do not understand common phrases oncologists use, such as “your tumor is progressing” or “your nodes are positive.”
Nivolumab plus ipilimumab did not prolong disease-free survival, and 43% of patients discontinued treatment due to toxicities.
The PFS benefit was driven primarily by patients with intermediate-risk disease.
MRI-based assessment shortened the time to correct treatment, when compared with TURBT, for patients with MIBC.
Adding a longer course of androgen deprivation therapy to postoperative radiotherapy may prolong metastasis-free survival in patients with prostate cancer.
An FDA pooled analysis suggests that certain AEs were associated with response and overall survival in PD-1/PD-L1-treated urothelial cancer.
Though uncommon, complete responses are seen among patients with metastatic disease, but CRs seem to occur more often with immune checkpoint inhibitors.